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ABSTRACT
Background COVID-19 appeared in late 2019, causing a 
pandemic spread. This led to a reorganisation of oncology 
care in order to reduce the risk of spreading infection 
between patients and healthcare staff. Here we analysed 
measures taken in major oncological units in Europe and 
the USA.
Methods A 46- item survey was sent by email to 
representatives of 30 oncological centres in 12 of the most 
affected countries. The survey inquired about preventive 
measures established to reduce virus spread, patient 
education and processes employed for risk reduction in 
each oncological unit.
Results Investigators from 21 centres in 10 countries 
answered the survey between 10 April and 6 May 2020. 
A triage for patients with cancer before hospital or 
clinic visits was conducted by 90.5% of centres before 
consultations, 95.2% before day care admissions and in 
100% of the cases before overnight hospitalisation by 
means of phone calls, interactive online platforms, swab 
test and/or chest CT scan. Permission for caregivers to 
attend clinic visits was limited in many centres, with some 
exceptions (ie, for non- autonomous patients, in the case 
of a new diagnosis, when bad news was expected and for 
terminally ill patients). With a variable delay period, the 
use of personal protective equipment was unanimously 
mandatory, and in many centres, only targeted clinical and 
instrumental examinations were performed. Telemedicine 
was implemented in 76.2% of the centres. Separated 
pathways for COVID-19- positive and COVID-19- negative 
patients were organised, with separate inpatient units and 
day care areas. Self- isolation was required for COVID-19- 
positive or symptomatic staff, while return to work policies 
required a negative swab test in 76.2% of the centres.
Conclusion Many pragmatic measures have been 
quickly implemented to deal with the health emergency 
linked to COVID-19, although the relative efficacy of 
each intervention should be further analysed in large 
observational studies.
INTRODUCTION
A novel coronavirus disease, named COVID-
19, responsible for SARS, appeared in late 
2019, originating most likely from a seafood 
market in Wuhan, in the Hubei province of 
China.1 The causative agent was identified 
as a new coronavirus, called SARS- CoV-2, 
phylogenetically similar to SARS- CoV-1, 
responsible for the SARS outbreak that 
occurred in 2002.2 SARS- CoV-2 derives from 
natural selection likely in bats or pangolins 
with zoonotic transfer, leading to high affinity 
binding to the human ACE2 receptor.3
COVID-19 infection has rapidly spread and 
was declared a pandemic by the WHO on 
11 March 2020. More than five million cases 
and more than 300 000 deaths have been 
reported in May worldwide.4 Several coun-
tries have adopted measures to limit virus 
spread, including lockdown, social distancing 
and reinforcement of hygiene requirements. 
Hospital activities have also been reorgan-
ised in order to reduce the risk of contagion 
among patients and caregivers.
Key questions
What is already known about this subject?
 ► The COVID-19 pandemic led to a reorganisation of 
oncological care, based on expert advice, in order to 
reduce the spread of infection between patients and 
healthcare staff.
What does this study add?
 ► The practical aspects of managing patients with 
cancer in multiple cancer centres during the 
COVID-19 health crisis have been analysed in this 
report. Many pragmatic measures have been quickly 
implemented, although the relative efficacy of each 
intervention should be further analysed in large ob-
servational studies.
How might this impact on clinical practice?
 ► This analysis could be extremely interesting from 
an organisational point of view for possible future 
epidemics, for countries actually at the peak of the 
pandemic and in case a second COVID-19 peak oc-
curs in the next months.
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Patients with cancer belong to a high- risk category for 
complications from infection due to organ damage from 
both tumour growth and treatment toxicity, immunosup-
pression resulting from tumour and anticancer therapies, 
and the generally advanced age group and presence of 
frequent comorbidities. Moreover, patients with cancer 
require frequent access to the hospital for assessment of 
disease status and toxicity, and in order to receive appro-
priate care, with increased risk of exposure to germs.
An analysis of 1524 patients admitted to a radiation 
and medical oncology unit in Wuhan from December 
2019 to February 2020 found a twofold increase of the 
risk of COVID-19 infection rate in patients with cancer 
compared with the general population (0.79% vs 0.37%) 
over the same period of time.5 Data derived from a nation-
wide analysis in China reported that COVID-19- positive 
patients with cancer (N=18) had a higher risk of severe 
events compared with patients without cancer (39% vs 
8%, p=0.0003), especially patients in active treatment 
compared with cancer survivors.6 In an Italian cohort 
published last March, 72 deaths out of 355 (20.3%) 
occurred in patients with cancer, while only 0.8% of 
the deaths occurred in patients without comorbidities, 
including cancer.7
Facing this exceptional and rapidly developing situa-
tion, no standard operating procedures for care organ-
isations existed in oncologiocal institutions, although 
general recommendations for healthcare in hospital 
units, for COVID-19 and suspected case management 
were rapidly drafted.8 Several recent expert statements 
have been published addressing how to manage care in 
specialist oncology departments, but few reports guide 
effective organisation for daily clinical practice.9–20 We 
aimed to assess how oncology centres and departments 
reacted to the health crisis related to the COVID-19 
pandemic, in order to improve oncological care and to 
implement preventive measures.
MATERIALS AND METHODS
A survey (online supplementary material) was sent by 
email to 30 representatives of oncological departments in 
12 of the most affected countries by COVID-19 in Europe 
and the USA in order to provide quality assessment.
The topics investigated in the survey included preven-
tive measures taken before and after admission to the 
hospital, instructions given to patients and professionals, 
general measures for risk reduction of virus spread, 
specific measures in the hospitalisation unit, general 
organisation of the centre, organisation of multidisci-
plinary meetings and activities of other healthcare profes-
sionals, staff management and antibody testing. The 
survey was composed of 46 items, for which response 
could be yes, no, not applicable or unknown. Addi-
tional information was provided by comments, such as 
describing procedures used in particular situations.
The survey was completed by all the centres over a 
short time period in order to avoid bias from changing 
practices, modification of diagnostic technologies and 
from national regulations on the availability and applica-
bility of tests and isolation procedures.
The data obtained are presented as a percentage of 
responses out of the total number of participating centres, 
and bar chart was used to summarise data on triage, 
screening and general measures taken for risk reduction 
and specific measures in inpatient units.
The burden on the health system for each country at 
the moment of the survey completion was reported as 
the number of affected cases per 100 000 inhabitants, 
with data extracted from the Johns Hopkins University 
COVID-19 Data Repository.4
RESULTS
Between 10 April and 6 May 2020, a total of 21 institu-
tions from 10 different countries answered the survey by 
email: from Belgium (5), Italy (4), Spain (2), Germany 
(2), Switzerland (2), USA (2), Austria (1), the Nether-
lands (1), France (1) and Luxembourg (1). Overall, 15 
centres were university general hospitals, 5 were compre-
hensive cancer centres and 1 was a private clinic. All the 
centres included experienced high- capacity oncological 
units. Among these, 21 centres had consultations and day 
care facilities, and 20 had an overnight facility.
The burden of COVID-19 cases on the health system is 
calculated as the number of total infections per 100 000 
inhabitants in each country (figure 1). However, consid-
ering the different applicability of the test in the acute 
phase of the outbreak in different countries, the number 
of cases does not fully reflect the real load of infection. At 
the moment of survey completion, a lower burden, with 
less than 200 cases per 100 000 inhabitants, was observed 
for France, Germany, Austria, the Netherlands and one 
centre from USA. For Italy, Belgium, Switzerland, Spain 
and the other centre from USA, 200–400 patients were 
affected by COVID-19 per 100 000 inhabitants. The most 
affected country was Luxembourg, with more than 500 
cases per 100 000 inhabitants.
Triage, screening procedures and patients’ education
Patients were subjected to a triage for signs of infection 
prior to presenting to the oncology units in the majority 
of the centres, notably in 19/21 institutions (90.5%) 
before consultations, in 20/21 (95.2%) before day care 
outpatient infusion room admissions and in 20/20 
(100%) before overnight hospitalisation (figure 2). More 
specifically, the triage/screening tools used were phone 
calls, interactive online platforms, nasopharyngeal or 
oropharyngeal swab tests, and/or chest CT scans. Phone 
call was the most common sorting method, used in 17/21 
(81%) institutions before outpatient consultations, in 
18/21 (85.7%) before day care admissions and in 18/20 
(90%) before hospitalisation. Less extensive use of the 
interactive online platform was noted: platforms were in 
implementation in two centres, routinely used in 4/21 
(19%) before consultations and day care unit admissions 
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and in 3/20 (15%) before hospitalisations. Swab test was 
not routinely performed for outpatients as it was used in 
only 2/21 centres (9.5%). Its use was more common for 
sorting patients in overnight wards, with 13/20 centres 
(65%) using it routinely on unselected patients prior to 
admission, with a result available within 12 hours in all the 
institutions. Chest CT scan was used in only one institu-
tion (4.8%) as a screening method before surgery and 
invasive procedures.
A clinical check of symptoms was performed in the 
hospital/clinic before entering the consultation room in 
17/21 centres (81%), before entering the day care unit 
in 20/21 (95.2%) and before hospitalisation in 19/20 
(95%) units.
Patients were educated in the majority of centres to 
take precautions in order to avoid virus transmission. In 
particular, 20/21 (95.2%) centres educated patients to 
contact the medical oncology/haematology department 
if they developed symptoms potentially related to COVID-
19, and in 19/21 (90.5%) centres, patients were advised 
to avoid visits to the unit in the presence of suspected 
symptoms.
Allowance of visitors with patients
Permission for family members and caregivers to accom-
pany patients was limited at this stage of pandemic 
spread, with only 8/21 (38.1%) centres allowing attend-
ance to consultations, 4/21 (19%) to day care admissions 
and 8/20 (40%) to visit patients in overnight wards. Some 
exceptions were allowed: in 17/21 (81%) centres when a 
patient was unable to enter without assistance, in case of 
a new diagnosis of cancer in 3/21 (14.3%) centres, when 
bad news has to be announced in 4/21 (19%) centres and 
for terminally ill patients in 18/20 (90%) hospitalisation 
units. Some centres implemented virtual meetings with 
the family concomitantly to physical meetings with the 
patients.
Protective equipment and disinfection
In addition to social distancing and frequent hand 
washing/disinfection, some general measures were imple-
mented to reduce risk of contagion (figure 3), such as the 
use of surgical masks for all patients in 19/21 (90.5%) 
institutions and for healthcare providers in all of the 21 
centres (100%), the use of non- sterile gloves for physical 
examinations in 12/21 (57.1%) and for nursing in 15/21 
(71.4%) centres. Filtering facepiece 2 and 3 masks were 
Figure 1 COVID-19 infection per 100 000 inhabitants. The curves represent the number of patients per 100 000 inhabitants 
with positive results for COVID-19 over time in the 10 countries included in the survey from 22 January to 13 May 2020. Each 
bar on the curves corresponds to one investigator. On the x- axis, the timing from February to May is shown; on the y- axis, the 
N of patients per 100 000 inhabitants is shown.
Figure 2 Triage/screening measures for COVID-19 in 
oncological units. Triage (phone call and on- line platform) 
and screening (swab test) measures taken before 
consultation, day care admission and hospitalisation in 21 
oncological units.
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used in 1/21 (4.8%) institutions for non- aerosolising 
procedures, if no previous swab test had been done.
Increased rates of disinfection process were also noted: 
of consultation rooms in 17/21 (81%) centres, of the day 
care units in 18/21 (85.7%) and of the hospitalisation 
units in 17/20 (85%) centres.
Reduction in physical contact
To reduce contact (figure 3), physical examination was 
abolished for asymptomatic patients in 16/21 (76.2%) 
centres, and a targeted examination was preferred when 
necessary, for example, of the known sites of metas-
tasis or directed by symptoms. Blood pressure control 
was performed only when clinically indicated and not 
routinely in 19/21 (90.5%) institutions. Blood sampling 
was reduced by at least 25% in 10/21 (47.6%) centres, 
and the number of CT scans for evaluation of tumour 
response was reduced by at least 25% in 11/21 (52.4%) 
institutions. The use of telemedicine was implemented in 
16/21 (76.2%) centres.
Several specific measures have been taken in inpa-
tient units to reduce patients’ stay and physical contacts 
(figure 4). Only private rooms were used in 7/20 (35%) 
centres; palliative care admissions were reduced in 10/20 
(50%) centres; chemotherapy was transferred from over-
night hospitalisation to day care unit in 5/20 (25%) 
centres. In 10/21 (47.6%) centres, physicians discussed 
the option to avoid intensive care in case of worsening 
of clinical conditions in those with terminal illness, 
regardless of COVID-19 infection, accepting the risk 
of early death. In 13/20 (65%) centres, swab tests were 
performed before hospitalisation, and in 10/20 (50%) 
centres, admissions were limited to COVID-19- negative 
patients. Two centres (10%) allow emergency admissions 
without a negative test result. Retesting during hospital-
isation was done in only two centres (10%), weekly (one 
centre) or biweekly (one centre). Nasopharyngeal or 
oropharyngeal swab test for healthcare staff in the hospi-
talisation unit was done weekly by only one centre and 
biweekly by another one, while 18/20 (90%) centres did 
not do swab testing for healthcare professionals in the 
absence of symptoms.
In the majority of the hospitals, specific COVID-19 
units separate from non- COVID units have been organ-
ised (20/21 centres, 95.2%), and nurses and medical staff 
Figure 3 General measure for risk reduction. Measures taken to reduce the risk of COVID-19 transmission in 21 oncological 
units.
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in the oncology unit participate exclusively to COVID-
19- negative patients’ care in 12/21 (57.1%) centres. In 
20/21 (95.2%) centres, specific pathways for COVID-
19- negative and COVID-19- positive/suspected patients 
have been organised. COVID-19- confirmed or suspected 
cases at or during hospitalisation were transferred to the 
COVID-19 units in 18/20 (90%) centres. Specific sepa-
rate day care units for COVID-19- positive/suspected cases 
were established in 9/21 (42.9%) institutions, while in 1 
(4.8%) case a specific room was used for these patients. 
At the start of the COVID-19 crisis, the oncology depart-
ment, either in part or in full, moved to another location 
in 4/21 (19%) centres, in the same hospital in three cases 
and to another hospital in one case.
Multidisciplinary meetings were done by videoconfer-
ences in 17/21 (81%) centres, while in 4/21 (19%) phys-
ical meetings were still done respecting social distancing. 
Multidisciplinary team members other than physician 
and nurses could still see patients in 10/21 (47.6%) 
centres, while in 16/21 (76.2%) centres, they managed 
all (10/21) or almost all (6/21) problems by phone or 
videoscreen.
Management of staff suspected or confirmed as having 
COVID-19
Self- isolation at home was the rule for staff members 
presenting with fever in 20/21 (95.2%) centres and for 
staff members living with someone in self- isolation in 
13/21 (61.9%) centres. Return to work for healthcare 
professionals tested COVID-19- positive was allowed after 
at least 7 days from diagnosis and 3 days without symptoms 
in 5/21 cases (23.8%). In the remaining cases (16/21, 
76.2%), a negative swab test was required. In particular, in 
three centres, swab testing needed to be done after at least 
2 weeks of self- isolation, and in three centres, two nega-
tive tests were required. In one (4.8%) centre, homework 
was allowed for staff members older than 60 years, with 
serious comorbidity or with cohabitant family members 
with serious morbidity.
In addition to the previously discussed testing methods, 
an emerging interest is the use of serology. During the 
survey period, this test was offered to healthcare workers 
in 8/21 (38.1%) centres, most frequently in the context of 
a research project (7/21: 33.3%), and to patients in 9/21 
(42.9%) centres, in four cases as clinical study (19%) and 
in five (23.8%) as routine practice.
DISCUSSION
The emergence of COVID-19 has caused a global health 
emergency, leading to multiple critical challenges. Not 
only do clinicians and healthcare workers need to manage 
an extremely high load of very critically ill patients, but 
also they need to identify ways to reduce the risk of intr-
ahospital contagion both among patients and health-
care staff while using available resources as efficiently as 
Figure 4 Specific measures in inpatient units. Measures taken to reduce the risk of COVID-19 transmission in 20 oncological 
hospitalisation units.
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possible. This, however, has often resulted in a lack of 
resources for routine patient care.
In the oncology field, the initial response has been 
focused on the protection of patients from the risk of infec-
tion. A shared approach, based on expert advice, includes 
limiting hospital access whenever possible, implementing 
of a triage prior to admission to the hospital, reducing 
unnecessary consultations and exams, delaying follow- up 
visits, giving priority to adjuvant and curative treatment 
over palliative ones, and avoiding advanced treatment 
lines with low probability of clinical benefit.9 10 In this 
context, the risk of jeopardising the effectiveness of 
cancer treatment and the risk of delayed diagnosis must 
be taken into high consideration and should be carefully 
analysed in future long- term studies.18
We conducted an observational study to analyse the 
activity of oncology centres located in the countries 
most affected by the COVID-19 outbreak. These types of 
studies are beneficial in order to identify best practices 
and to construct standardised algorithms for the preven-
tion and management of this virus, and other emerging 
viruses, at long- term. It is especially crucial in light of a 
likely secondary recrudescence of the infection outbreak.
While for some aspects the applied procedures were 
almost the same in all centres, others were quite different 
between centres, probably due to different burden of 
infection, differences in the availability of viral screening 
and resource availability.
The use of personal protective equipment was one of 
the cornerstones for prevention of virus spread that was 
almost unanimously accepted. Another interesting point 
is reducing the number of people accessing the hospital 
by limiting those accompanying or visiting patients. This 
second strategy is not currently used in all centres, due to 
the particular needs of patients with cancer. Therefore, a 
limitation of the number of persons could be applied to 
routine visits or access to the hospital during treatment, 
while exceptions can be made for heavily dependent 
patients, when bad news has to be announced and for 
terminally ill patients.
The use of telemedicine reduces patient exposure to the 
hospital and is actually used in 76.2% of the institutions. 
Although some legal and reimbursement issues remain, 
COVID-19 crisis has led to a rapid expansion of telemed-
icine, which could remain a good option also outside the 
pandemic crisis, especially when a clinical examination is 
not necessary and in areas of the world where reaching 
the hospital raises practical difficulties for patients.21
Almost all the oncological centres included in the survey 
performed a triage before admission to the hospital in 
order to recognise symptoms early in suspected cases and 
to avoid contamination of other patients and healthcare 
professionals. Triage is supplemented with diagnostic 
tests, usually swab, with nasal sampling resulting more 
efficiently than throat sampling.22 23 The main issue with 
this tool is the relatively low sensitivity of about 70%, the 
multiplicity of primers that can be used to perform the 
reverse- transcriptase polymerase chain reaction (RT- PCR) 
and the risk of cross- reactivity with other coronavirus 
strains.24–26 Chest CT scan seems to be more sensitive than 
RT- PCR for COVID-19 diagnosis and in 60%–93% of the 
cases becomes positive before the RT- PCR.25 27 However, 
the disadvantage of CT is the limited availability in terms 
of number of exams per day in each institution compared 
with the swab, which can be easily made on a large scale 
and is less cost- effective. On the other hand, the result of 
the swab test takes a longer time than CT scan. A potential 
solution to these concerns is the development of a rapid 
test, such as the serological test for IgA, IgM and IgG. 
Currently, its low sensitivity at the early phase of infec-
tion, the delayed and the lower rate of seroconversion 
in patients with cancer and the inability to detect conta-
giousness do not yet make it a suitable test to be used as a 
diagnostic standard.28–30 Overall, at the moment, it seems 
more appropriate to carry out a triage by telephone or 
interactive platform before outpatient admissions and a 
swab before hospitalisation. While the use of screening 
by means of a swab prior to hospitalisation is increasing, 
there was no unanimous agreement about retesting. A 
single baseline test does not allow early detection of intra-
hospital infections and could miss paucisymptomatic or 
presymptomatic patients.31
Another issue of concern is the implementation of a 
policy for return to work for healthcare professionals 
tested positive. While some centres require negative swab 
test, others do not, which may pose a risk of transmitting 
the infection at the workplace, considering that a duration 
of viral shedding up to 37 days has been described.32 33
Finally, predisposed dedicated facilities to manage 
cancer care during COVID-19 pandemic could be advis-
able.34 Although COVID-19 wards have been organised 
in most centres, in only 57.1% of the centres healthcare 
professionals caring for oncohaematological patients did 
not take part in the care of COVID-19- positive patients.
In conclusion, we analysed the prevention measures 
taken in oncological units in high- income countries in 
Europe and the USA, which effectiveness could be assessed 
in a later stage of the pandemic and in large observational 
studies. Although some recommendations for hospital 
management during the COVID-19 pandemic are actu-
ally available, such as those of the European Centre for 
Disease Prevention and Control, our study allows assess-
ment of adherence to this recommendation, in addition 
to providing an insight into the management of oncolog-
ical care during the pandemic in a real- world context.8 
Many procedures adopted, in fact, require agreement 
at the international level. Some critical issues remain to 
be improved in order to increase the safety of treatment 
for oncohaematological patients. The same level of care 
should be extended to the entire healthcare system, to 
less well- supplied centres and to low- income countries.
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